UNSPSC 51121536: Bucromarone

This classification denotes an antiarrhythmic agent with the molecular formula C29H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JI688O846T, chemically known as 4h-1-benzopyran-4-one, 2-(4-(3-(dibutylamino)propoxy)-3,5-dimethylbenzoyl)- but generally known as bucromarone, which bears US NIH Compound Identifier 132852. European Medicines Agency schedules Bucromarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05953MIG.

UNSPSC 51121536 Bucromarone, a Commodity code, covers pharmaceutical products supplied to state and local health systems, emergency services, and managed Medicaid programs. State and local governments procure medications and pharmaceutical products under this code to support emergency medical services, public health programs, and pharmacy benefit initiatives. The issuing bodies span city fire departments, state health and human services agencies, and multi-state cooperative purchasing alliances; procurement occurs through a mix of sealed competitive bids, requests for proposal, and requests for information as agencies evaluate direct-to-manufacturer strategies and consolidated purchasing models.

Recent activity reflects two primary procurement patterns. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with four specific medication line items—Labetalol, Epinephrine, Adenosine, and Diltiazem—with an estimated contract value of $40,000 and a response deadline of April 8, 2026; the bid included a 5 percent small local business enterprise discount and required vendors to meet nine-month expiration standards and one-year warranty obligations. The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting strategies outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) closing March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and meet cGMP and Drug Supply Chain Security Act compliance standards. Geographic activity centers on Florida, Texas, and Minnesota, with cooperative purchasing extending across multiple states.